Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUL 13 ... therapy to address the multiple causes of conjunctivitis. Dual action against viral and bacterial conjunctivitis is important because when an infection is diagnosed it is difficult, time-consuming and ...
2009 SEP 28 ... ophthalmic ointment is approved for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery. It is the only product approved for ...
2009 JUN 8 ... Currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis, Inspire has initiated two Phase II randomized placebo-controlled clinical trials of ...
2009 JUN 16 ... of levofloxacin 0.5% eyedrops with the classic, more frequent dosing in patients with bacterial conjunctivitis. A total of 120 patients with symptoms of...
2009 JUN 22 ... 1%), InSite's topical antibiotic eye drop currently marketed for the treatment of bacterial conjunctivitis, or dexamethasone, a commonly used corticosteroid intended to address inflammation. ...
2009 NOV 23 ... (azithromycin ophthalmic solution) 1%, InSite Vision's product for the treatment of bacterial conjunctivitis, increased by 50 percent over the third quarter 2008. Inspire ...
2009 JUN 29 ... Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat® for allergic conjunctivitis and royalties based on net ...
2009 SEP 21 ... routinely used in neonates for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery. If not treated, the infection can be ...
2009 NOV 16 ... routinely used in neonates for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery. Corporate Completed a public ...
2009 SEP 21 ... Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat® for allergic conjunctivitis and royalties based on ...
2009 NOV 2 ... Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat® (epinastine HCl ophthalmic solution) 0.05% for ...
2009 SEP 21 ... approved in several years. Allergic conjunctivitis, not to be confused with viral or bacterial conjunctivitis or pink eye, is an eye allergy that often results in ocular itching, and I am excited ...
2009 AUG 24 ... MinuteClinic nurse practitioners to accurately diagnose whether a patient has viral or bacterial conjunctivitis. Practitioners can then identify a proper course of treatment and eliminate unnecessary ...
2009 OCT 5 ... corneal complications were observed in five AKC patients, including two cases of bacterial corneal ulcer and three cases of herpetic keratitis; all of these patients were ... Novel Cyclosporine 0.1% Aqueous Ophthalmic Solution in the Treatment of Severe Allergic Conjunctivitis. Journal of Ocular Pharmacology and Therapeutics, 2009;25(4):365-371). For ...
2009 SEP 21 ... novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced the start of a Phase 2a proof-of-concept study ... company. NovaBay also is currently engaged in clinical studies of NVC-422 for viral conjunctivitis with its other major partner Alcon (NYSE:ACL), the world's leading eye care company. ...
2009 JUN 8 ... ophthalmic suspension 0.6% is a new topical fluoroquinolone for the treatment of bacterial conjunctivitis. Besifloxacin has potent in vitro activity against a broad spectrum of ocular pathogens, ...
2009 JUN 29 ... of besifloxacin ophthalmic suspension 0.6% with that of vehicle in the treatment of bacterial conjunctivitis. Research design and methods: This was a randomized, multicenter, double-masked, ...
2009 OCT 12 ... suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis. Multicenter, randomized, double-masked, parallel-group, active-controlled, ...
2009 OCT 5 ... daily (TID) topical ocular administration to human subjects with clinically diagnosed bacterial conjunctivitis, maximum besifloxacin concentrations in plasma were less than 0.5 ng/mL, on average," ...
2009 OCT 12 ... (30.7%), and Staphylococcus aureus (23%). The incidence of concurrent infection (mainly bacterial infection) strongly correlated with the percent of eosinophilic cells. Concurrent ... to evaluate in a large series the incidence of latent infection during chronic allergic conjunctivitis. In a 5-year follow-up prospective, nonrandomized trial, we evaluated 236 patients (472 ...
